FlippingBook

946 / 1983

Why should we continue to discuss about ART?
1Arcangeli S et al. Crit Rev Oncol Hematol. 2016 Jan;97:322-7
2Hoffman Ke et al, J Urol. 2011; 185 (1): 116–120
- These trials typically represent a paradigm of the time
delay-related limitations 1
- Indeed, only 20% of the patients potentially candidate
to ART really receive it2
- Introduction of the PSA dosage and of the concept of
early salvage RT (SRT)